Author: Eton Pharmaceuticals

Posted Date:

May 12, 2026

Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

Eton Pharmaceuticals

May 12, 2026
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Eton Pharmaceuticals

May 4, 2026
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution

Eton Pharmaceuticals

May 1, 2026
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

Eton Pharmaceuticals

April 27, 2026
Eton Pharmaceuticals Announces CFO Succession Plan

Eton Pharmaceuticals

April 16, 2026
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Eton Pharmaceuticals

March 19, 2026
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

Eton Pharmaceuticals

March 3, 2026
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

Eton Pharmaceuticals

March 2, 2026
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

Eton Pharmaceuticals

February 25, 2026
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

Eton Pharmaceuticals

February 20, 2026